Evaluation of new anti-infective drugs for the treatment of acute pelvic infections in hospitalized women

D. L. Hemsell, J. S. Solomkin, Richard L Sweet, F. Tally, J. G. Bartlett

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This set of guidelines deals with evaluation of anti-infective drugs for treatment of acute pelvic infections in hospitalized women. The clinical entities include infectious complications of cesarean section; elective hysterectomy; and septic, incomplete abortion. Conditions including endomyometritis, cuff cellulitis, pelvic cellulitis, parametritis, phlegmon, and pelvic abscesses may arise due to a variety of bacterial species, both aerobic and anaerobic, that comprise the endogenous flora of the lower reproductive tract. Anaerobic bacteria have assumed particular importance, and therapy should be directed against such organisms. The roles of enterococci, chlamydiae, and mycoplasmas remain uncertain. Culture samples must be obtained under conditions assuring minimal vaginal contamination. Before a new drug may be used for treatment of human pelvic infections, considerable information is necessary about its antimicrobial spectrum as well as its safety and efficacy. Placebo-controlled trials are considered unethical. Historical controls may be used, but concurrent active control comparative trials are preferred. Parenteral administration is recommended for at least the initial 4 days of therapy, but orally administered drugs may be evaluated for completion of longer courses. The expected cure rate is ~90%. Uncomplicated infections should be treated for at least 4 days; more complicated infections may require prolonged therapy. Although clinical cure is paramount, microbiologic response must also be taken into account. In the final assessment, outcome will be classified as cure, failure, or indeterminate.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume15
Issue numberSUPPL. 1
StatePublished - 1992

Fingerprint

Pelvic Infection
Parametritis
Cellulitis
Pharmaceutical Preparations
Septic Abortion
Incomplete Abortion
Therapeutics
Endometritis
Anaerobic Bacteria
Chlamydia
Mycoplasma
Enterococcus
Infection
Hysterectomy
Cesarean Section
Abscess
Placebos
Guidelines
Safety

ASJC Scopus subject areas

  • Immunology

Cite this

Evaluation of new anti-infective drugs for the treatment of acute pelvic infections in hospitalized women. / Hemsell, D. L.; Solomkin, J. S.; Sweet, Richard L; Tally, F.; Bartlett, J. G.

In: Clinical Infectious Diseases, Vol. 15, No. SUPPL. 1, 1992.

Research output: Contribution to journalArticle

Hemsell, D. L. ; Solomkin, J. S. ; Sweet, Richard L ; Tally, F. ; Bartlett, J. G. / Evaluation of new anti-infective drugs for the treatment of acute pelvic infections in hospitalized women. In: Clinical Infectious Diseases. 1992 ; Vol. 15, No. SUPPL. 1.
@article{8f8c3c7a23d64a3cb4404cab2fa7b31e,
title = "Evaluation of new anti-infective drugs for the treatment of acute pelvic infections in hospitalized women",
abstract = "This set of guidelines deals with evaluation of anti-infective drugs for treatment of acute pelvic infections in hospitalized women. The clinical entities include infectious complications of cesarean section; elective hysterectomy; and septic, incomplete abortion. Conditions including endomyometritis, cuff cellulitis, pelvic cellulitis, parametritis, phlegmon, and pelvic abscesses may arise due to a variety of bacterial species, both aerobic and anaerobic, that comprise the endogenous flora of the lower reproductive tract. Anaerobic bacteria have assumed particular importance, and therapy should be directed against such organisms. The roles of enterococci, chlamydiae, and mycoplasmas remain uncertain. Culture samples must be obtained under conditions assuring minimal vaginal contamination. Before a new drug may be used for treatment of human pelvic infections, considerable information is necessary about its antimicrobial spectrum as well as its safety and efficacy. Placebo-controlled trials are considered unethical. Historical controls may be used, but concurrent active control comparative trials are preferred. Parenteral administration is recommended for at least the initial 4 days of therapy, but orally administered drugs may be evaluated for completion of longer courses. The expected cure rate is ~90{\%}. Uncomplicated infections should be treated for at least 4 days; more complicated infections may require prolonged therapy. Although clinical cure is paramount, microbiologic response must also be taken into account. In the final assessment, outcome will be classified as cure, failure, or indeterminate.",
author = "Hemsell, {D. L.} and Solomkin, {J. S.} and Sweet, {Richard L} and F. Tally and Bartlett, {J. G.}",
year = "1992",
language = "English (US)",
volume = "15",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Evaluation of new anti-infective drugs for the treatment of acute pelvic infections in hospitalized women

AU - Hemsell, D. L.

AU - Solomkin, J. S.

AU - Sweet, Richard L

AU - Tally, F.

AU - Bartlett, J. G.

PY - 1992

Y1 - 1992

N2 - This set of guidelines deals with evaluation of anti-infective drugs for treatment of acute pelvic infections in hospitalized women. The clinical entities include infectious complications of cesarean section; elective hysterectomy; and septic, incomplete abortion. Conditions including endomyometritis, cuff cellulitis, pelvic cellulitis, parametritis, phlegmon, and pelvic abscesses may arise due to a variety of bacterial species, both aerobic and anaerobic, that comprise the endogenous flora of the lower reproductive tract. Anaerobic bacteria have assumed particular importance, and therapy should be directed against such organisms. The roles of enterococci, chlamydiae, and mycoplasmas remain uncertain. Culture samples must be obtained under conditions assuring minimal vaginal contamination. Before a new drug may be used for treatment of human pelvic infections, considerable information is necessary about its antimicrobial spectrum as well as its safety and efficacy. Placebo-controlled trials are considered unethical. Historical controls may be used, but concurrent active control comparative trials are preferred. Parenteral administration is recommended for at least the initial 4 days of therapy, but orally administered drugs may be evaluated for completion of longer courses. The expected cure rate is ~90%. Uncomplicated infections should be treated for at least 4 days; more complicated infections may require prolonged therapy. Although clinical cure is paramount, microbiologic response must also be taken into account. In the final assessment, outcome will be classified as cure, failure, or indeterminate.

AB - This set of guidelines deals with evaluation of anti-infective drugs for treatment of acute pelvic infections in hospitalized women. The clinical entities include infectious complications of cesarean section; elective hysterectomy; and septic, incomplete abortion. Conditions including endomyometritis, cuff cellulitis, pelvic cellulitis, parametritis, phlegmon, and pelvic abscesses may arise due to a variety of bacterial species, both aerobic and anaerobic, that comprise the endogenous flora of the lower reproductive tract. Anaerobic bacteria have assumed particular importance, and therapy should be directed against such organisms. The roles of enterococci, chlamydiae, and mycoplasmas remain uncertain. Culture samples must be obtained under conditions assuring minimal vaginal contamination. Before a new drug may be used for treatment of human pelvic infections, considerable information is necessary about its antimicrobial spectrum as well as its safety and efficacy. Placebo-controlled trials are considered unethical. Historical controls may be used, but concurrent active control comparative trials are preferred. Parenteral administration is recommended for at least the initial 4 days of therapy, but orally administered drugs may be evaluated for completion of longer courses. The expected cure rate is ~90%. Uncomplicated infections should be treated for at least 4 days; more complicated infections may require prolonged therapy. Although clinical cure is paramount, microbiologic response must also be taken into account. In the final assessment, outcome will be classified as cure, failure, or indeterminate.

UR - http://www.scopus.com/inward/record.url?scp=0026452646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026452646&partnerID=8YFLogxK

M3 - Article

C2 - 1477250

AN - SCOPUS:0026452646

VL - 15

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 1

ER -